Page last updated: 2024-11-13
lithium orotate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 23686432 |
SCHEMBL ID | 161884 |
MeSH ID | M0066623 |
Synonyms (15)
Synonym |
---|
einecs 226-081-4 |
l2n7z24b30 , |
unii-l2n7z24b30 |
lithium 1,2,3,6-tetrahydro-2,6-dioxopyrimidine-4-carboxylate |
4-pyrimidinecarboxylic acid, 1,2,3,6-tetrahydro-2,6-dioxo-, monolithium salt |
5266-20-6 |
4-pyrimidinecarboxylic acid, 1,2,3,6-tetrahydro-2,6-dioxo-, lithium salt (1:1) |
lithium orotate |
SCHEMBL161884 |
lithium orotate [who-dd] |
lithium orotate [vandf] |
DTXSID9063748 |
lithium 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylate |
Q6647963 |
lithium;2,4-dioxo-1h-pyrimidine-6-carboxylate |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" Intriguingly, lithium orotate (LiOr) is suggested to possess unique uptake characteristics that would allow for reduced dosing and mitigation of toxicity concerns." | ( Different pharmacokinetics of lithium orotate inform why it is more potent, effective, and less toxic than lithium carbonate in a mouse model of mania. Bekar, LK; Pacholko, AG, 2023) | 1.55 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 2 (33.33) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 55.97
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (55.97) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 2 (25.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (75.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |